Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.
about
Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.Tumor necrosis factor-associated periodic syndrome in adults.TNF-α potentiates uric acid-induced interleukin-1β (IL-1β) secretion in human neutrophils.
P2860
Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Canakinumab reverses overexpre ...... -associated periodic syndrome.
@en
Canakinumab reverses overexpre ...... -associated periodic syndrome.
@nl
type
label
Canakinumab reverses overexpre ...... -associated periodic syndrome.
@en
Canakinumab reverses overexpre ...... -associated periodic syndrome.
@nl
prefLabel
Canakinumab reverses overexpre ...... -associated periodic syndrome.
@en
Canakinumab reverses overexpre ...... -associated periodic syndrome.
@nl
P2093
P2860
P1476
Canakinumab reverses overexpre ...... -associated periodic syndrome.
@en
P2093
Ken Abrams
Marco Cattalini
Marco Gattorno
Martin Letzkus
Nanguneri Nirmala
Nicole Hartmann
Rebecca Torene
Roberta Caorsi
Sandrine Starck-Schwertz
Vincent Tormey
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-209335
P407
P577
2016-07-29T00:00:00Z